Multi Radiance Medical (MRM) has announced that the U.S. Food and Drug Administration (FDA) has granted NHN 510(k) clearance for the MR5 ACTIV PRO Super Pulsed Laser, specifically for the temporary relief of pain associated with lateral epicondylitis, commonly known as tennis elbow. This condition affects approximately 10.5 million adults globally each year, primarily impacting those engaged in repetitive activities that stress the elbow. A recent triple-blind, placebo-controlled clinical trial demonstrated that 72% of participants receiving the active treatment achieved clinical success, compared to 40% in the placebo group (p=0.045). The findings, published in BMJ Open, reinforce MRM's commitment to evidence-based, non-invasive treatment options for musculoskeletal pain. This new indication complements existing FDA clearances for treating fibromyalgia and neck and shoulder pain, expanding the clinical applications of MRM's technology. MRM's leadership emphasized the importance of scientific rigor in validating their treatments, ensuring healthcare professionals can confidently provide effective, drug-free options for patients suffering from pain.